Drug - Alecensa® (alectinib) [Genentech, Inc.]
Therapeutic area - Oncology
- Patient must be 18 years of age or older AND
- Patient must have a diagnosis of anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
Maximum of 240 capsules per 30 days.
MHCP Provider Call Center 651-431-2700 or 800-366-5411